Upfront Briefing
Lilly kept the checkbook open, signing an Insilico Medicine R&D collaboration and commercialization deal valued at up to $2.75B.
On the M&A tape, Otsuka agreed to acquire Transcend Therapeutics for $700M upfront and up to $525M in milestones — a meaningful marker for private CNS pricing.
And in late-stage immunology, Takeda posted full Phase 3 psoriasis data for zasocitinib, sharpening the case for a 2026 FDA filing and adding fresh scrutiny to its roughly $4B TYK2 bet.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,368.9 |
(1.7%) |
(7.1%) |
| Nasdaq 100 |
23,132.8 |
(1.9%) |
(8.2%) |
| Russell 2000 |
2,449.7 |
(1.7%) |
(2.3%) |
| Healthcare (XLV) |
143.3 |
(1.7%) |
(7.5%) |
| Biotech (XBI) |
119.6 |
(3.5%) |
(1.6%) |
| Nasdaq Biotech (NBI) |
5,549.4 |
(2.9%) |
(2.8%) |
| Clinical Trials (BBC) |
39.6 |
(3.9%) |
+5.2% |
|
- Risk-off was broad: the S&P 500 fell (1.7%), the Nasdaq 100 dropped (1.9%), and the Russell 2000 slipped (1.7%) as Iran-war escalation kept oil elevated and pushed investors to price in a nastier inflation/growth mix into quarter-end.
- Biotech beta did not hide: XBI (3.5%), NBI (2.9%) and BBC (3.9%) all underperformed as investors cut higher-volatility healthcare exposure rather than hiding in speculative SMID-cap biotech.
- Healthcare was defensive only in relative terms: XLV also fell (1.7%), but held up better than biotech as capital rotated away from long-duration risk and toward balance-sheet quality.
- Market data: U.S. close Fri 27-Mar-2026.
The Big 3
|
1
|
Insilico Medicine, Lilly sign deal worth up to $2.75B
|
- Insilico Medicine and Lilly signed an R&D collaboration and commercialization deal worth up to $2.75 billion, including $115 million upfront. Lilly gets an exclusive worldwide license to select preclinical oral programs plus a multi-program discovery collaboration, expanding the pair’s existing relationship around AI-enabled small-molecule discovery.
- The disclosed assets are still preclinical rather than late-stage de-risked molecules, so the signal here is less about clinical data and more about partner willingness to pay meaningful upfront dollars before human proof-of-concept when the output is a licensable oral asset package.
- Why it matters: This is more than a generic “AI validation” headline. Lilly is underwriting AI-enabled external R&D with real upfront capital against asset-backed preclinical programs, which matters because it raises the bar from software demos to molecules with ownership economics. For investors, the read-through is strongest for platforms that can consistently convert AI into partnerable compounds rather than discovery narratives.
- Source: Reuters
- More: PR
|
|
2
|
Otsuka to acquire Transcend Therapeutics for $700M upfront plus milestones
|
- Otsuka agreed to acquire Transcend Therapeutics for $700 million upfront and up to $525 million in sales milestones. The deal gives Otsuka TSND-201 (methylone), a rapid-acting neuroplastogen being developed for PTSD and other psychiatric conditions.
- The asset matters because PTSD remains a high-unmet-need market with no new approved therapies in roughly 25 years, and Transcend has been positioning TSND-201 around a shorter in-clinic treatment model than legacy psychedelic-style approaches. The program is still earlier than a registrational asset, but it is far enough along to give strategics something more tangible than platform-only optionality.
- Why it matters: This is a meaningful pricing marker for private CNS: Otsuka is paying real upfront dollars for a differentiated clinical-stage PTSD asset rather than waiting for full late-stage de-risking. For investors, that supports the idea that neuropsychiatry programs can still command strategic valuations when the mechanism is novel, the treatment paradigm is commercially workable, and the indication offers obvious whitespace.
-
Source:
Endpoints
-
More: PR
|
| 3 | Takeda posts full Phase 3 psoriasis data on $4B TYK2 bet |
- Takeda posted full Phase 3 AAD data for zasocitinib in moderate-to-severe plaque psoriasis, strengthening the case for a 2026 FDA filing and sharpening the oral TYK2 competitive set.
- Per the AAD readout, PASI 90 rates at Week 16 were 61.3% and 51.9% versus 5.0% and 4.0% for placebo and 16.8% and 15.9% for Otezla; PASI 100 rates were 33.4% and 25.2% versus 0.7% and 1.1% for placebo and 2.9% and 4.3% for Otezla. That is the kind of dataset investors need to start underwriting competitive positioning rather than just filing probability.
-
Why it matters: This is a high-value clinical and strategic update. Takeda paid roughly $4 billion for Nimbus’ TYK2 program, so strong Phase 3 follow-through matters not just for psoriasis positioning versus Sotyktu and other oral immunology assets, but also for how investors underwrite large external-R&D bets in late-stage immunology. A credible path to filing turns the debate from “does the asset work?” to “how much share can an oral TYK2 with competitive efficacy capture?”
-
Source:
Fierce Biotech
-
More: Fierce Biotech
|
Everything Else that broke
- White House seeks pharma support for drug pricing bill focused on most-favored-nation pricing. — STAT
- EMA backs EU authorization for Imdylltra (tarlatamab) in relapsed ES-SCLC. — EMA
- EMA CHMP backs four new medicines in March and recommended a subcutaneous form of Sanofi's Sarclisa. — BioCentury
- Novartis says NEJM Phase 3 APPLAUSE-IgAN data showed Fabhalta slowed kidney function decline by 49.3%. — PR
- Biogen posts positive Phase 2 litifilimab data in cutaneous lupus at AAD26. — Endpoints
- Incyte posted new 54-week Phase 3 hidradenitis suppurativa data showing durable symptom reduction for povorcitinib. — Reuters
- FDA approves Rocket's KRESLADI for pediatric severe LAD-I, shifting the story from CMC overhang to PRV monetization and ultra-rare launch execution. — Reuters
- AstraZeneca's tozorakimab notched a win in COPD trials. — BioPharma Dive
- AstraZeneca in vivo CAR-T showed early responses but included one death in a China trial. — Endpoints
- EMA validates Tryngolza (olezarsen) label-expansion filing in severe hypertriglyceridemia. — PR
- Idorsia reports Phase 2 daridorexant results in children with insomnia disorder. — PR
- Nanobiotix to present first randomized Phase 2 data for JNJ-1900 (NBTXR3) in stage 3 inoperable lung cancer. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Insilico Medicine and Lilly sign R&D and commercialization deal worth up to $2.75B, including $115M upfront. — Reuters
- Otsuka to acquire Transcend Therapeutics for $700M upfront and up to $525M in milestones. — PR
- ICYMI: Novartis to buy Excellergy in allergy deal worth up to $2B. — PR
VC / Private Financings
- Anaptys approved the First Tracks spin-off; the newco secured $145M of commitments, including an $80M oversubscribed private placement backed by 683 Capital, Adage, Affinity, Ally Bridge, Janus Henderson, Point72, TCGX and others; Anaptys also authorized a $100M buyback. — PR
- Vor Bio announced a $75M private placement led by new investor TCGX to fund development of telitacicept. — PR
- Artelo to raise $11.0M in at-the-market private placement. — PR
IPOs / Follow-Ons
- Kailera Therapeutics filed for a U.S. IPO around its Phase 3 obesity drug licensed from Hengrui. — Reuters
Things that make you go hmmm ...
Look: Life Sciences Firepower Reserves. Source: EY.
Academic Corner - DASH-patterned groceries and effects on blood pressure in adults treated for hypertension: the GoFreshRx randomized trial. — Nature Medicine
- Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial. — Lancet
- A Phase 3 Trial of Brepocitinib in Dermatomyositis. — NEJM
|
